Sana Biotechnology, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Sana raised $93.3 million in Q2 2026 ($25.0 million from Mayo Clinic equity investment plus ATM offerings), bringing cash to $160.5 million with runway into mid-2027. Company progressed SC451 (HIP-modified islet cells for type 1 diabetes) and SG293 (CD8-targeted CAR T for non-Hodgkin lymphoma) toward IND filings and Phase 1/2 trials expected as early as late 2026. UP421 showed positive 14-month durability data published in NEJM; Mayo collaboration targets SC451 development acceleration.
Why this rating
Mayo $25M investment is ~8.5% of market cap; $93.3M financing is ~32% of market cap. Decent capital raise extends runway but company burns ~$69.3M per half-year. Clinical progress notable but early-stage; no patient efficacy data yet. Moderate significance relative to company size and stage.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.